Clin Pharmacokinet
-
Esmolol is a unique cardioselective β(1)-receptor blocking agent with a rapid onset and short duration of action. Since our previous review in 1995, the pharmacokinetics and efficacy of esmolol have been investigated in a number of acute care settings. Three studies investigated the pharmacokinetics and safety of esmolol in the paediatric population. ⋯ However, for the prevention of postoperative atrial fibrillation esmolol provides no advantage over oral β-blockers. In other situations where emergent β-blockade is required, such as electroconvulsive therapy, esmolol has been shown to effectively control haemodynamic response. After more than 2 decades of use esmolol continues to provide an important therapeutic option in the acute care setting.